All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional. If you are a patient or carer, please visit the MPN Advocates Network.
During the 64th American Society of Hematology (ASH) Annual Meeting and Exposition, the MPN Hub was pleased to speak to Claire Harrison, Guy’s and St Thomas’ NHS Foundation Trust, London, UK. We asked, Can JAK2V617F variant allele frequency (VAF) variations help predict clinical and survival outcomes?
Can JAK2V617F VAF variations help predict clinical and survival outcomes?
Harrison opens by discussing the latest data presented at the 64th ASH Annual Meeting and Exposition from a range of studies on the relationship between JAK2V617F VAF variations and progression-free survival, event-free survival, overall survival, and molecular response. Harrison concludes by outlining the promising developments for molecular monitoring in the field of myeloproliferative neoplasms.
ASH 2022 abstracts: What’s hot in MPN?
To help navigate the exciting content being presented at the 64th American Society of Hematology (ASH) Annual Meeting and Exposition, the MPN Hub Steering Committee have provided their recommendations for the...
Genetic testing in the diagnosis and management of patients with BCR-ABL1-negative myeloproliferative neoplasms
Genetic and genomic testing are of increasing importance in the diagnosis and management of patients with hematologic neoplasms....
Subscribe to get the best content related to MPN delivered to your inbox